Cancer

Patient sample, cell culture and mouse studies suggest EZH2 inhibitors could help treat CARM1-positive ovarian cancers. In serous ovarian cancer patients, levels of CARM1 were higher in tumors than in normal ovarian epithelial cells, and the high CARM1 levels correlated with poor overall survival. In a human ovarian cancer cell line, the EZH2 inhibitor GSK2816126 increased apoptosis in cells expressing high levels of CARM1 compared with CARM1-knockout cells. In an orthotopic xenograft mouse model of CARM1-positive ovarian cancer, GSK2816126 decreased tumor growth and increased survival compared with vehicle. Next steps include evaluating CARM1 as marker to predict response to EZH2 inhibitors in ovarian cancer patients...